KR20050009723A - 신규 에토노게스트렐 에스테르 - Google Patents

신규 에토노게스트렐 에스테르 Download PDF

Info

Publication number
KR20050009723A
KR20050009723A KR10-2004-7019330A KR20047019330A KR20050009723A KR 20050009723 A KR20050009723 A KR 20050009723A KR 20047019330 A KR20047019330 A KR 20047019330A KR 20050009723 A KR20050009723 A KR 20050009723A
Authority
KR
South Korea
Prior art keywords
etonogestrel
hrt
dodecanoate
undecanoate
female
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7019330A
Other languages
English (en)
Korean (ko)
Inventor
데니즈스헨릭
반데르부르트헨트리쿠스아드리아누스안토니우스
라이센디르크
그루텐휘스아리얀
Original Assignee
악조 노벨 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악조 노벨 엔.브이. filed Critical 악조 노벨 엔.브이.
Publication of KR20050009723A publication Critical patent/KR20050009723A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR10-2004-7019330A 2002-05-30 2003-05-22 신규 에토노게스트렐 에스테르 Ceased KR20050009723A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02077119.2 2002-05-30
EP02077119 2002-05-30
PCT/EP2003/050187 WO2003102012A2 (en) 2002-05-30 2003-05-22 New etonogestrel esters

Publications (1)

Publication Number Publication Date
KR20050009723A true KR20050009723A (ko) 2005-01-25

Family

ID=29595014

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7019330A Ceased KR20050009723A (ko) 2002-05-30 2003-05-22 신규 에토노게스트렐 에스테르

Country Status (30)

Country Link
US (1) US7323454B2 (enExample)
EP (1) EP1513861B1 (enExample)
JP (1) JP4716726B2 (enExample)
KR (1) KR20050009723A (enExample)
CN (2) CN1314701C (enExample)
AR (1) AR040130A1 (enExample)
AT (1) ATE349458T1 (enExample)
AU (1) AU2003238081B2 (enExample)
BR (1) BR0311254A (enExample)
CA (1) CA2487722C (enExample)
CO (1) CO5631449A2 (enExample)
DE (1) DE60310714T2 (enExample)
DK (1) DK1513861T3 (enExample)
ES (1) ES2277085T3 (enExample)
HR (1) HRP20041101A2 (enExample)
IL (1) IL165087A0 (enExample)
IS (1) IS2421B (enExample)
MX (1) MXPA04011797A (enExample)
NO (1) NO20044898L (enExample)
NZ (1) NZ536619A (enExample)
PE (1) PE20040068A1 (enExample)
PL (1) PL373855A1 (enExample)
PT (1) PT1513861E (enExample)
RS (1) RS97604A (enExample)
RU (1) RU2325910C2 (enExample)
SI (1) SI1513861T1 (enExample)
TW (1) TW200403065A (enExample)
UA (1) UA80126C2 (enExample)
WO (1) WO2003102012A2 (enExample)
ZA (1) ZA200410410B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2721832C (en) 2008-04-17 2018-08-07 Micell Technologies, Inc. Stents having bioabsorbable layers
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
RU2595818C1 (ru) * 2015-05-25 2016-08-27 Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона"
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB845442A (en) 1956-03-22 1960-08-24 Schering Ag Manufacture of steroid compounds
DE1013284B (de) 1956-03-22 1957-08-08 Schering Ag Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen
GB8313921D0 (en) 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
CN1135716A (zh) * 1993-12-27 1996-11-13 阿克佐诺贝尔公司 经皮吸收的药用制剂
WO1997003709A1 (de) 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
DE19613698A1 (de) 1995-07-17 1997-01-23 Schering Ag Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
TR200003743T2 (tr) 1998-06-19 2001-07-23 Akzo Nobel N.V. Testosteron türevi.
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters

Also Published As

Publication number Publication date
UA80126C2 (en) 2007-08-27
CA2487722A1 (en) 2003-12-11
CN1314701C (zh) 2007-05-09
RU2325910C2 (ru) 2008-06-10
IS2421B (is) 2008-10-15
SI1513861T1 (sl) 2007-06-30
JP4716726B2 (ja) 2011-07-06
CN101100480A (zh) 2008-01-09
ATE349458T1 (de) 2007-01-15
MXPA04011797A (es) 2005-03-31
HRP20041101A2 (en) 2004-12-31
CO5631449A2 (es) 2006-04-28
RS97604A (sr) 2006-10-27
DE60310714D1 (de) 2007-02-08
EP1513861A2 (en) 2005-03-16
BR0311254A (pt) 2005-03-15
CA2487722C (en) 2011-07-19
DE60310714T2 (de) 2007-10-11
WO2003102012A9 (en) 2005-01-13
JP2005532350A (ja) 2005-10-27
US20050222113A1 (en) 2005-10-06
TW200403065A (en) 2004-03-01
WO2003102012A3 (en) 2004-04-22
IS7528A (is) 2004-11-15
PE20040068A1 (es) 2004-02-18
NZ536619A (en) 2007-09-28
ZA200410410B (en) 2006-02-22
US7323454B2 (en) 2008-01-29
WO2003102012A2 (en) 2003-12-11
AU2003238081A1 (en) 2003-12-19
AU2003238081B2 (en) 2008-09-18
ES2277085T3 (es) 2007-07-01
PT1513861E (pt) 2007-03-30
AR040130A1 (es) 2005-03-16
IL165087A0 (en) 2005-12-18
CN1692122A (zh) 2005-11-02
RU2004138807A (ru) 2005-05-27
DK1513861T3 (da) 2007-04-10
NO20044898L (no) 2005-02-25
HK1072609A1 (en) 2005-09-02
PL373855A1 (en) 2005-09-19
EP1513861B1 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
CA2487722C (en) New etonogestrel esters
ES2245694T3 (es) Derivados de 11beta-pentil- y 11beta-hexil-estra-1,3,5(10)-trienos sustituidos en la posicion 8beta.
KR100396902B1 (ko) 19-노르-프레그넨유도체및이를함유하는약학적조성물
RU2386637C2 (ru) 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ С ИЗБИРАТЕЛЬНОЙ ЭСТРОГЕННОЙ АКТИВНОСТЬЮ
FI88509B (fi) 9-alfa,11-beta-nitro-substituerade och 11-beta-nitro-substituerade estraner
RU2322986C2 (ru) Применение новых сложных эфиров этоногестрела
US20050234027A1 (en) 17alpha-fluorosteroids, pharmaceutical compositions containing 17alpha-fluorosteroids and a method of making them
HK1072609B (en) New etonogestrel esters
HK1072568B (en) Use of new etonogestrel esters
KR20070061557A (ko) 선택적 에스트로겐 활성을 보이는 15β-치환 스테로이드

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20041129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20070227

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080516

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100728

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101015

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100728

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I